CompletedNot Applicable

Comparison Between Darbapoeitin Alpha and Roxadustat in CKD-related Anemia

Egypt35 participantsStarted 2024-06-01

Plain-language summary

Anemia is a common and debilitating complication of end-stage kidney disease (ESKD) that is associated with reduced quality of life and high morbidity and mortality. ESKD-related anemia is associated with many adverse comorbidities and outcomes; however, normalizing the levels of hemoglobin proved to be insignificant in improving most adverse outcomes. This study aims to evaluate the real-world effectiveness and safety of an ESA and a HIF-PHI in patients with CKD-related anemia.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * End-stage kidney disease-related anemia * Hemodialysis-related anemia * The mean of the two most recent Hemoglobin values before randomization was 10.5mg/dL or less Exclusion Criteria: * ESA treatment 12 weeks before transfusion * RBC transfusion 8 weeks before transfusion * IV iron transfusion 6 weeks before transfusion * Known history of myelodysplastic syndrome * Known history of multiple myeloma * Known history of hereditary hematologic diseases * Active bleeding or any cause of anemia unrelated to CKD * NYHA Class III or IV congestive heart failure * Liver disease, defined as ALT or AST 3x ULN or greater, or total bilirubin 1.5x ULN or greater * Prior organ transplant

What they're measuring

Change in Iron profile

Timeframe: 12 weeks

Trial details

NCT IDNCT07517744

SponsorAin Shams University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2025-06-12

View on ClinicalTrials.gov More CKD Anemia trials